

studies are usually appropriate, but realistically speaking, why would industry fund studies that have an excellent chance of showing what a number of smaller studies have already shown, especially since they are making a lot of money in that market already? And, if a larger study were negative, wouldn't there be cries to do even larger ones? After all, one can really never prove a negative. There is always the possibility that another slight twist or an even larger study could be positive. If it takes a very large number of subjects to show a significant positive result, the clinical benefit must be difficult to uncover. At some point, one has to conclude that enough is enough and we have to accept the results at hand. In the meantime, large amounts of money are being diverted from better uses in our health care system.

MAYER B. DAVIDSON, MD

From the Clinical Center for Research Excellence, Charles R. Drew University, Los Angeles, California. Address correspondence to Mayer B. Davidson, MD, Charles R. Drew University, Clinical Center for Research Excellence, 1731 E. 120th St., Los Angeles, CA 90059. E-mail: madavids@cdrewu.edu.

© 2006 by the American Diabetes Association.

References

- 1. Neeser K, Erny-Albrecht KM, Weber C: Cost-effectiveness of self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin (Letter). *Diabetes Care* 29:480, 2006
2. Davidson MB: Counterpoint: self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin: a waste of money (Editorial). *Diabetes Care* 28:1531-1533, 2005
3. Welschen LMC, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WAB, Bouter LM: Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. *Diabetes Care* 28:1510-1517, 2005

An Evaluation of the Efficacy of Methods Used in Screening for Lower-Limb Arterial Disease in Diabetes

Response to Williams et al.

We have read with interest the report by Williams et al. (1) on diabetic limbs without critical ischemia. We have recently performed a

similar study in 106 diabetic patients with polyneuropathy, 61 of whom had critical ischemia (2), which confirms the poor performance of ankle-brachial pressure index in these patients (1,2). At variance to Williams et al. (1), we were, however, able to demonstrate the usefulness of the pulsatility index to predict critical ischemia. A pulsatility index <1.2 recorded at the ankle arteries predicted critical limb ischemia with reasonably good sensitivity (0.87) and specificity (0.62); the positive and the negative predictive values were 0.64 and 0.86, respectively. We explain our differences to the findings of Williams et al. by the different Doppler devices that were employed. While Williams et al. had used a 8-MHz Doppler probe (1), we used a 10-MHz linear ultrasound probe with a color-flow duplex machine (Accuson 128XP10; Acuson, Mountain View, CA) in our study.

ALFRED JANSSEN, MD
ERNST CHANTELAU, MD, PHD

From the MNR-Klinik, Heinrich-Heine-University of Düsseldorf/Germany, Düsseldorf, Germany. Address correspondence to Ernst Chantelau, MD, PhD, MNR-Klinik, Heinrich-Heine-University of Düsseldorf/Germany, POB 10 10 07, D-40001 Düsseldorf, Germany. E-mail: lobnig@med.uni-duesseldorf.de.

© 2006 by the American Diabetes Association.

References

- 1. Williams DT, Harding KG, Price P: An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes. *Diabetes Care* 28:2206-2210, 2005
2. Janssen A: Pulsatility index is better than ankle-brachial Doppler index for non-invasive detection of critical limb ischaemia in diabetes. *VASA* 34:235-241, 2005

An Evaluation of the Efficacy of Methods Used in Screening for Lower-Limb Arterial Disease in Diabetes

Response to Janssen and Chantelau

We thank Janssen and Chantelau (1) for their interest in our study (2), which analyzed the efficacy of several commonly used lower-limb arterial screening modalities in diabetes.

We demonstrated that qualitative, operator interpretation of the continuous Doppler waveform at the ankle for limbs without critical ischemia was more sensitive than quantitative analysis in detecting peripheral arterial occlusive disease. In our hands, qualitative waveform analysis achieved a sensitivity of 94% and specificity of 66% in the presence of clinically detectable peripheral neuropathy. Pulsatility index and other quantitative waveform analyses invariably failed to detect more severe peripheral arterial occlusive disease, with an overall sensitivity of 52%. In your study of limbs with and without critical ischemia, pulsatility index was demonstrated to achieve greater sensitivity at 87% (3).

There appear to be two fundamental differences between the respective studies. First, this study focused on the ability of commonly used screening methods to detect hemodynamically significant arterial disease not their ability to predict the presence of critical ischemia. Patients with critical ischemia were therefore excluded from our study. Further, we employed a relatively simple, single-crystal, continuous waveform analyzer and not a more complex device with a linear crystal array and color-flow facility. Color duplex imaging with waveform analysis of the lower limb has been demonstrated to be effective in detecting peripheral arterial occlusive disease (4). Our study used this modality as a gold standard not as a screening modality.

It is not surprising, therefore, that the results of quantitative analysis differ between the two studies.

DEAN T. WILLIAMS, MD
KEITH G. HARDING, MD
PATRICIA PRICE, PHD

From the Wound Healing Research Unit, Department of Surgery, University of Wales College of Medicine, Cardiff, U.K.

Address correspondence to Dean T. Williams, MD, Wound Healing Research Unit, Department of Surgery and Cardiff Institute of Tissue Engineering and Repair, Cardiff University, U.K. CF14 4UJ. E-mail: dwill1964@aol.com.

© 2006 by the American Diabetes Association.

References

- 1. Janssen A, Chantelau E: An evaluation of the efficacy of methods used in screening for lower-limb arterial disease in diabetes (Letter). *Diabetes Care* 29:481, 2006
2. Williams DT, Harding KG, Price P: An evaluation of the efficacy of methods used in screening for lower-limb arterial dis-